Cargando…

An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques

The recent spread of Zika virus (ZIKV) through the Americas and Caribbean and its devastating consequences for pregnant women and their babies have driven the search for a safe and efficacious ZIKV vaccine. Among the vaccine candidates, a first-generation ZIKV purified inactivated vaccine (ZPIV), ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Lecouturier, Valérie, Pavot, Vincent, Berry, Catherine, Donadieu, Arnaud, de Montfort, Aymeric, Boudet, Florence, Rokbi, Bachra, Jackson, Nicolas, Heinrichs, Jon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067768/
https://www.ncbi.nlm.nih.gov/pubmed/32194996
http://dx.doi.org/10.1038/s41541-020-0167-8
_version_ 1783505449795977216
author Lecouturier, Valérie
Pavot, Vincent
Berry, Catherine
Donadieu, Arnaud
de Montfort, Aymeric
Boudet, Florence
Rokbi, Bachra
Jackson, Nicolas
Heinrichs, Jon
author_facet Lecouturier, Valérie
Pavot, Vincent
Berry, Catherine
Donadieu, Arnaud
de Montfort, Aymeric
Boudet, Florence
Rokbi, Bachra
Jackson, Nicolas
Heinrichs, Jon
author_sort Lecouturier, Valérie
collection PubMed
description The recent spread of Zika virus (ZIKV) through the Americas and Caribbean and its devastating consequences for pregnant women and their babies have driven the search for a safe and efficacious ZIKV vaccine. Among the vaccine candidates, a first-generation ZIKV purified inactivated vaccine (ZPIV), adjuvanted with aluminum hydroxide, developed by the Walter Reed Army Institute of Research (WRAIR), has elicited high seroconversion rates in participants in three phase-I clinical trials. In collaboration with the WRAIR, Sanofi Pasteur (SP) optimized the production scale, culture and purification conditions, and increased the regulatory compliance, both of which are critical for clinical development and licensure of this vaccine. Using a clinical batch of the first-generation ZPIV as a benchmark, we report that different doses of the optimized vaccine (ZPIV-SP) elicited sustained neutralizing antibodies, specific T- and memory B-cells, and provided complete protection against a ZIKV challenge in cynomolgus macaques. These data provide evidence that the ZPIV-SP vaccine performs at least as well as the ZPIV vaccine, and provide support for continued development in the event of future ZIKV outbreaks.
format Online
Article
Text
id pubmed-7067768
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70677682020-03-19 An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques Lecouturier, Valérie Pavot, Vincent Berry, Catherine Donadieu, Arnaud de Montfort, Aymeric Boudet, Florence Rokbi, Bachra Jackson, Nicolas Heinrichs, Jon NPJ Vaccines Article The recent spread of Zika virus (ZIKV) through the Americas and Caribbean and its devastating consequences for pregnant women and their babies have driven the search for a safe and efficacious ZIKV vaccine. Among the vaccine candidates, a first-generation ZIKV purified inactivated vaccine (ZPIV), adjuvanted with aluminum hydroxide, developed by the Walter Reed Army Institute of Research (WRAIR), has elicited high seroconversion rates in participants in three phase-I clinical trials. In collaboration with the WRAIR, Sanofi Pasteur (SP) optimized the production scale, culture and purification conditions, and increased the regulatory compliance, both of which are critical for clinical development and licensure of this vaccine. Using a clinical batch of the first-generation ZPIV as a benchmark, we report that different doses of the optimized vaccine (ZPIV-SP) elicited sustained neutralizing antibodies, specific T- and memory B-cells, and provided complete protection against a ZIKV challenge in cynomolgus macaques. These data provide evidence that the ZPIV-SP vaccine performs at least as well as the ZPIV vaccine, and provide support for continued development in the event of future ZIKV outbreaks. Nature Publishing Group UK 2020-03-12 /pmc/articles/PMC7067768/ /pubmed/32194996 http://dx.doi.org/10.1038/s41541-020-0167-8 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Lecouturier, Valérie
Pavot, Vincent
Berry, Catherine
Donadieu, Arnaud
de Montfort, Aymeric
Boudet, Florence
Rokbi, Bachra
Jackson, Nicolas
Heinrichs, Jon
An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
title An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
title_full An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
title_fullStr An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
title_full_unstemmed An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
title_short An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
title_sort optimized purified inactivated zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067768/
https://www.ncbi.nlm.nih.gov/pubmed/32194996
http://dx.doi.org/10.1038/s41541-020-0167-8
work_keys_str_mv AT lecouturiervalerie anoptimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT pavotvincent anoptimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT berrycatherine anoptimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT donadieuarnaud anoptimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT demontfortaymeric anoptimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT boudetflorence anoptimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT rokbibachra anoptimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT jacksonnicolas anoptimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT heinrichsjon anoptimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT lecouturiervalerie optimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT pavotvincent optimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT berrycatherine optimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT donadieuarnaud optimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT demontfortaymeric optimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT boudetflorence optimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT rokbibachra optimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT jacksonnicolas optimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques
AT heinrichsjon optimizedpurifiedinactivatedzikavaccineprovidessustainedimmunogenicityandprotectionincynomolgusmacaques